Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion Inc (ACONW) delivers innovative healthcare solutions through its Nociscan platform, combining MR spectroscopy and AI-driven diagnostics to address chronic low back pain. This page serves as the definitive source for official company announcements and medically validated progress updates.
Access timely updates on clinical trial results, strategic partnerships, and technological enhancements directly from the source. Investors and medical professionals will find curated information spanning product developments, research collaborations, and business milestones – all essential for understanding the company's position in medical diagnostics.
Our repository includes verified reports on biomarker validation studies, SaaS platform updates, and healthcare provider adoption metrics. Bookmark this page to efficiently track Aclarion's progress in transforming spine care through noninvasive diagnostic innovation.
Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.
Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.
Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.
FAQ
What is the current stock price of ACLARION (ACONW)?
